Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables - Other: 2015-2023

Historic Receivables - Other for Intellia Therapeutics (NTLA) over the last 7 years, with Dec 2023 value amounting to $1.0 million.

  • Intellia Therapeutics' Receivables - Other fell 37.50% to $1.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.0 million, marking a year-over-year decrease of 37.50%. This contributed to the annual value of $1.0 million for FY2023, which is 37.50% down from last year.
  • Intellia Therapeutics' Receivables - Other amounted to $1.0 million in Q4 2023, which was down 0.00% from $1.0 million recorded in Q3 2023.
  • Intellia Therapeutics' 5-year Receivables - Other high stood at $8.4 million for Q1 2020, and its period low was $100,000 during Q4 2021.
  • Over the past 3 years, Intellia Therapeutics' median Receivables - Other value was $1.0 million (recorded in 2023), while the average stood at $888,889.
  • Per our database at Business Quant, Intellia Therapeutics' Receivables - Other tumbled by 88.10% in 2021 and then skyrocketed by 1,500.00% in 2022.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Receivables - Other stood at $3.6 million in 2019, then climbed by 20.00% to $1.2 million in 2020, then slumped by 83.33% to $100,000 in 2021, then skyrocketed by 1,500.00% to $1.6 million in 2022, then crashed by 37.50% to $1.0 million in 2023.
  • Its last three reported values are $1.0 million in Q4 2023, $1.0 million for Q3 2023, and $1.4 million during Q2 2023.